Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 29 publications
IGNITE: a phase III study of tirabrutinib versus rituximab and temozolomide combination therapy in relapsed/refractory primary central nervous system lymphoma.
Journal: Future oncology (London, England)
Published: June 19, 2026
Updated Overall Survival and Long-Term Safety With Ripretinib Versus Sunitinib in Patients With GI Stromal Tumor: Final Overall Survival Analysis From INTRIGUE.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: May 23, 2025
The INSIGHT study: a randomized, Phase III study of ripretinib versus sunitinib for advanced gastrointestinal stromal tumor with KIT exon 11 + 17/18 mutations.
Journal: Future oncology (London, England)
Published: September 04, 2024
Vimseltinib versus placebo for tenosynovial giant cell tumour (MOTION): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial.
Journal: Lancet (London, England)
Published: March 29, 2024
CSF1R Inhibition in Patients with Advanced Solid Tumors or Tenosynovial Giant Cell Tumor: A Phase I Study of Vimseltinib.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: March 05, 2024
The MOTION study: a randomized, phase III study of vimseltinib for the treatment of tenosynovial giant cell tumor.
Journal: Future oncology (London, England)
Published: August 18, 2023
Patient-reported outcomes and tolerability in patients receiving ripretinib versus sunitinib after treatment with imatinib in INTRIGUE, a phase 3, open-label study.
Journal: European journal of cancer (Oxford, England : 1990)
Published: April 17, 2023
Ripretinib Versus Sunitinib in Patients With Advanced Gastrointestinal Stromal Tumor After Treatment With Imatinib (INTRIGUE): A Randomized, Open-Label, Phase III Trial.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: August 10, 2022
Clinical Benefit of Ripretinib Dose Escalation After Disease Progression in Advanced Gastrointestinal Stromal Tumor: An Analysis of the INVICTUS Study.
Journal: The oncologist
Published: May 28, 2021
A Phase 3 Trial of Luspatercept in Patients with Transfusion-Dependent β-Thalassemia.
Journal: The New England journal of medicine
Published: March 27, 2020
Last Updated: 09/26/2026